Treat to target strategy in early rheumatoid arthritis versus routine care - A comparative clinical practice study.

[1]  R. Caporali,et al.  In early inflammatory polyarthritis more intensive management according to the 2010 ACR/EULAR criteria leads to higher rates of clinical remission: comparison of two cohorts treated according to different treat-to-target protocols. , 2017, Clinical and experimental rheumatology.

[2]  Tsutomu Takeuchi,et al.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update , 2010, Annals of the rheumatic diseases.

[3]  M. Wiese,et al.  Effect of Adherence to Protocolized Targeted Intensifications of Disease-modifying Antirheumatic Drugs on Treatment Outcomes in Rheumatoid Arthritis: Results from an Australian Early Arthritis Cohort , 2016, The Journal of Rheumatology.

[4]  Inge Christoffer Olsen,et al.  Ultrasound in management of rheumatoid arthritis: ARCTIC randomised controlled strategy trial , 2016, British Medical Journal.

[5]  J. Smolen.  Treat-to-target as an approach in inflammatory arthritis , 2016, Current opinion in rheumatology.

[6]  C. Allaart,et al.  Evaluating Adherence to a Treat‐to‐Target Protocol in Recent‐Onset Rheumatoid Arthritis: Reasons for Compliance and Hesitation , 2016, Arthritis care & research.

[7]  M. A. van de Laar,et al.  Recently diagnosed rheumatoid arthritis patients benefit from a treat-to-target strategy: results from the DREAM registry , 2016, Clinical Rheumatology.

[8]  M. Dougados,et al.  Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update , 2015, Annals of the rheumatic diseases.

[9]  M. Dougados,et al.  Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force , 2015, Annals of the rheumatic diseases.

[10]  H. Kautiainen,et al.  Impact of physicians’ adherence to treat-to-target strategy on outcomes in early rheumatoid arthritis in the NEO-RACo trial , 2015, Scandinavian journal of rheumatology.

[11]  C. Torp‐Pedersen,et al.  Why do we need observational studies of everyday patients in the real-life setting? , 2015 .

[12]  P. Geusens,et al.  Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial , 2014, Annals of the rheumatic diseases.

[13]  Jeffrey N Katz,et al.  Review: Treat to Target in Rheumatoid Arthritis: Fact, Fiction, or Hypothesis? , 2014, Arthritis & rheumatology.

[14]  J. Jacobs,et al.  The separate impact of tight control schemes and disease activity on quality of life in patients with early rheumatoid arthritis: results from the CAMERA trials. , 2014, Clinical and experimental rheumatology.

[15]  J. Greenberg,et al.  Patient Perspectives on Achieving Treat‐to‐Target Goals: A Critical Examination of Patient‐Reported Outcomes , 2013, Arthritis care & research.

[16]  J. Sampalis,et al.  Treating to a Target in Established Active Rheumatoid Arthritis Patients Receiving a Tumor Necrosis Factor Inhibitor: Results From a Real‐World Cluster‐Randomized Adalimumab Trial , 2013, Arthritis care & research.

[17]  V. Bykerk,et al.  The new ACR/EULAR remission criteria: rationale for developing new criteria for remission. , 2012, Rheumatology.

[18]  H. H. Kuper,et al.  Adherence to a treat-to-target strategy in early rheumatoid arthritis: results of the DREAM remission induction cohort , 2012, Arthritis Research & Therapy.

[19]  T. Kvien,et al.  Two-year direct and indirect costs for patients with inflammatory rheumatic joint diseases: data from real-life follow-up of patients in the NOR-DMARD registry. , 2012, Rheumatology.

[20]  T. Pincus,et al.  Treat-to-target: not as simple as it appears. , 2012, Clinical and experimental rheumatology.

[21]  H. H. Kuper,et al.  A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring registry , 2011, Annals of the rheumatic diseases.

[22]  B. Dijkmans,et al.  Aggressive therapy in patients with early arthritis results in similar outcome compared with conventional care: the STREAM randomized trial , 2011, Rheumatology.

[23]  H. H. Kuper,et al.  Implementation of a treat-to-target strategy in very early rheumatoid arthritis: results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study. , 2011, Arthritis and rheumatism.

[24]  B. Dijkmans,et al.  The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study , 2011, Annals of the rheumatic diseases.

[25]  David T Felson,et al.  UvA-DARE (Digital Academic Repository) American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials , 2011 .

[26]  M. Dougados,et al.  Disease activity score-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis: data from the GUEPARD trial and ESPOIR cohort , 2011, Annals of the rheumatic diseases.

[27]  C. Bombardier,et al.  Systematic Monitoring of Disease Activity Using an Outcome Measure Improves Outcomes in Rheumatoid Arthritis , 2010, The Journal of Rheumatology.

[28]  John Wong,et al.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs , 2010, Annals of the rheumatic diseases.

[29]  Maurizio Cutolo,et al.  Treating rheumatoid arthritis to target: recommendations of an international task force , 2010, Annals of the rheumatic diseases.

[30]  T. Kvien,et al.  Identification of Cutpoints for Acceptable Health Status and Important Improvement in Patient-Reported Outcomes, in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis , 2010, Journal of Rheumatology.

[31]  Y. Goekoop-Ruiterman,et al.  DAS-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis , 2009, Annals of the rheumatic diseases.

[32]  S SmolenJosef,et al.  EULAR (欧州リウマチ学会) 合成および疾患修飾性抗リウマチ生物学的製剤による関節リウマチ管理に関する推奨ガイドライン | 文献情報 | J-GLOBAL 科学技術総合リンクセンター , 2010 .

[33]  T. Pincus,et al.  Rheumatoid arthritis: strategy more important than agent , 2009, The Lancet.

[34]  M. Uffmann,et al.  Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score , 2005, Arthritis research & therapy.

[35]  A. McMahon,et al.  Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial , 2004, The Lancet.

[36]  P. Tugwell,et al.  A simplified disease activity index for rheumatoid arthritis for use in clinical practice. , 2003, Rheumatology.

[37]  Jan Abel Olsen,et al.  The role of adaptation to disability and disease in health state valuation: a preliminary normative analysis. , 2002, Social science & medicine.

[38]  M. Prevoo,et al.  Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. , 1995, Arthritis and rheumatism.

[39]  A. Williams.  EuroQol : a new facility for the measurement of health-related quality of life , 1990 .

[40]  A. Kasuya.  EuroQol--a new facility for the measurement of health-related quality of life. , 1990, Health policy.